216 related articles for article (PubMed ID: 31431548)
1. Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression.
Wang Q; Su L
mBio; 2019 Aug; 10(4):. PubMed ID: 31431548
[TBL] [Abstract][Full Text] [Related]
2. Vpr Targets TET2 for Degradation by CRL4
Lv L; Wang Q; Xu Y; Tsao LC; Nakagawa T; Guo H; Su L; Xiong Y
Mol Cell; 2018 Jun; 70(5):961-970.e5. PubMed ID: 29883611
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Accessory Protein Vpr Interacts with REAF/RPRD2 To Mitigate Its Antiviral Activity.
Gibbons JM; Marno KM; Pike R; Lee WJ; Jones CE; Ogunkolade BW; Pardieu C; Bryan A; Fu RM; Warnes G; Rowley PA; Sloan RD; McKnight Á
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776272
[TBL] [Abstract][Full Text] [Related]
4. Vpr overcomes macrophage-specific restriction of HIV-1 Env expression and virion production.
Mashiba M; Collins DR; Terry VH; Collins KL
Cell Host Microbe; 2014 Dec; 16(6):722-35. PubMed ID: 25464830
[TBL] [Abstract][Full Text] [Related]
5. Mannose receptor is an HIV restriction factor counteracted by Vpr in macrophages.
Lubow J; Virgilio MC; Merlino M; Collins DR; Mashiba M; Peterson BG; Lukic Z; Painter MM; Gomez-Rivera F; Terry V; Zimmerman G; Collins KL
Elife; 2020 Mar; 9():. PubMed ID: 32119644
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Vpr Induces Degradation of Gelsolin, a Myeloid Cell-Specific Host Factor That Reduces Viral Infectivity by Inhibiting the Expression and Packaging of the HIV-1 Env Glycoprotein.
Fabryova H; Kao S; Sukegawa S; Miyagi E; Taylor L; Ferhadian D; Saito H; Schaal H; Hillebrand F; Strebel K
mBio; 2023 Feb; 14(1):e0297322. PubMed ID: 36602307
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Vpr increases Env expression by preventing Env from endoplasmic reticulum-associated protein degradation (ERAD).
Zhang X; Zhou T; Frabutt DA; Zheng YH
Virology; 2016 Sep; 496():194-202. PubMed ID: 27343732
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
9. IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag.
Ahi YS; Yimer D; Shi G; Majdoul S; Rahman K; Rein A; Compton AA
mBio; 2020 Jan; 11(1):. PubMed ID: 31964738
[TBL] [Abstract][Full Text] [Related]
10. Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.
Misra A; Gleeson E; Wang W; Ye C; Zhou P; Kimata JT
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321330
[TBL] [Abstract][Full Text] [Related]
11. Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages.
Zhao L; Wang S; Xu M; He Y; Zhang X; Xiong Y; Sun H; Ding H; Geng W; Shang H; Liang G
Nat Commun; 2021 Jun; 12(1):3691. PubMed ID: 34140527
[TBL] [Abstract][Full Text] [Related]
12. Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection.
Beitari S; Pan Q; Finzi A; Liang C
J Virol; 2020 Jul; 94(16):. PubMed ID: 32493821
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Gag Recruits Oligomeric Vpr via Two Binding Sites in p6, but Both Mature p6 and Vpr Are Rapidly Lost upon Target Cell Entry.
Wanaguru M; Bishop KN
J Virol; 2021 Aug; 95(17):e0055421. PubMed ID: 34106747
[TBL] [Abstract][Full Text] [Related]
14. The phosphorylation of HIV-1 Gag by atypical protein kinase C facilitates viral infectivity by promoting Vpr incorporation into virions.
Kudoh A; Takahama S; Sawasaki T; Ode H; Yokoyama M; Okayama A; Ishikawa A; Miyakawa K; Matsunaga S; Kimura H; Sugiura W; Sato H; Hirano H; Ohno S; Yamamoto N; Ryo A
Retrovirology; 2014 Jan; 11():9. PubMed ID: 24447338
[TBL] [Abstract][Full Text] [Related]
15. Vpr-GFP virion particle identifies HIV-infected targets and preserves HIV-1Vpr function in macrophages and T-cells.
Muthumani K; Montaner LJ; Ayyavoo V; Weiner DB
DNA Cell Biol; 2000 Mar; 19(3):179-88. PubMed ID: 10749170
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Vpx-Mediated SAMHD1 and Vpr-Mediated Host Helicase Transcription Factor Degradation by Selective Disruption of Viral CRL4 (DCAF1) E3 Ubiquitin Ligase Assembly.
Wang H; Guo H; Su J; Rui Y; Zheng W; Gao W; Zhang W; Li Z; Liu G; Markham RB; Wei W; Yu XF
J Virol; 2017 May; 91(9):. PubMed ID: 28202763
[TBL] [Abstract][Full Text] [Related]
17. Functional Mapping of Regions Involved in the Negative Imprinting of Virion Particle Infectivity and in Target Cell Protection by Interferon-Induced Transmembrane Protein 3 against HIV-1.
Appourchaux R; Delpeuch M; Zhong L; Burlaud-Gaillard J; Tartour K; Savidis G; Brass A; Etienne L; Roingeard P; Cimarelli A
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355696
[TBL] [Abstract][Full Text] [Related]
18. Virion-targeted viral inactivation: new therapy against viral infection.
Okui N; Kitamura Y; Kobayashi N; Sakuma R; Ishikawa T; Kitamura T
Mol Urol; 2001; 5(2):59-66. PubMed ID: 11690549
[TBL] [Abstract][Full Text] [Related]
19. Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells.
Miller CM; Akiyama H; Agosto LM; Emery A; Ettinger CR; Swanstrom RI; Henderson AJ; Gummuluru S
J Virol; 2017 Jul; 91(13):. PubMed ID: 28424288
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation.
Tedbury PR; Novikova M; Alfadhli A; Hikichi Y; Kagiampakis I; KewalRamani VN; Barklis E; Freed EO
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
